NDAORALTABLET
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
PREMARIN (estrogens, conjugated) by Pfizer is estrogen receptor agonists [moa]. Approved for moderate to severe vasomotor symptoms due to menopause, moderate to severe vulvar, vaginal atrophy due to menopause () and 10 more indications. First approved in 2003.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREMARIN is an oral tablet containing conjugated estrogens that act as estrogen receptor agonists to treat moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, as well as hypoestrogenism and certain cancers in both women and men. It works by binding to estrogen receptors in target tissues to modulate hormone levels and reduce menopausal symptoms. The drug is indicated for a broad range of estrogen-deficiency conditions across multiple patient populations.
LOE Approaching
As a long-standing franchise approaching loss of exclusivity, PREMARIN brand teams face intensifying generic competition and shifting focus toward lifecycle extension or managed decline strategies.
Mechanism of Action
Estrogen Receptor Agonists
Worked on PREMARIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.